Abstract This article reviews the current literature addressing the treatment of schizophrenia with vitamin supplementation. It describes the important roles that vitamins play in normal metabolism, and reviews the evidence pertaining to vitamin deficiency and supplementation in patients with schizophrenia.
Introduction
Schizophrenia is a devastating and usually chronic illness associated with functional disability in social, cognitive, and emotional realms. It is characterized by positive symptoms (hallucinations, delusions), negative symptoms (emotional blunting, apathy), as well as cognitive impairment. While positive symptoms often respond to antipsychotic medication, negative symptoms and cognitive deficits do not. There is an urgent need for pharmacologic treatment beyond current antipsychotic medications to address these residual symptoms, which contribute substantially to functional impairment [1, 2] . Numerous investigators have associated schizophrenia with vitamin deficiencies, either after the illness has been diagnosed or during prenatal development [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Vitamin supplementation could provide therapeutic benefits through separate mechanisms of action than our current medication regimens, which focus largely on monoamine and histamine signaling.
Vitamins are organic compounds that are generally supplied in the diet; many are unable to be synthesized in adequate amounts by the human body. Vitamins are classified as water-soluble and fat-soluble. Most of the nine water-soluble vitamins act as coenzymes in metabolic processes; only one (vitamin K) of the four fat-soluble vitamins has a coenzyme role. Fat-soluble vitamins are absorbed and stored within the liver and adipose tissue [14] . To prevent a variety of medical illnesses caused by vitamin deficiencies, the Food and Drug Administration has issued specific recommendations for daily vitamin intake [15] (see Table 1 ). Of note, patients with schizophrenia often take in a high caloric diet that is high in saturated fats with poor fruit and fiber intake [16] .
In this article we review the literature addressing both vitamin deficiency and treatment in patients with schizophrenia. Data for this review were obtained from PubMed Table 2 ). Keyword searches included 'vitamin supplementation schizophrenia' and 'vitamin schizophrenia clinical trial.' Additionally, a search was performed for each individual vitamin combined with 'schizophrenia' (e.g., 'vitamin A schizophrenia'). Additional articles were obtained by searching references listed in the initial article list generated. We included only articles that involved measurement of vitamin levels in cohorts of schizophrenia or human clinical trials addressing the treatment of the primary symptoms of schizophrenia (i.e., not for medication sideeffect treatment). We did not include individual case reports. The search was limited to articles published in English.
Brief Historical Perspective
While this review focuses primarily on the current body of literature, it is worth putting it into some historical context. One of the earliest investigators to examine vitamin treatment for schizophrenia was Canadian psychiatrist Abraham Hoffer, who began his work in the 1950s and was a proponent of 'orthomolecular psychiatry,' which included treating with high doses of vitamins and nutrients. He argued that standard treatment of schizophrenia plus treatment with vitamin B3 ''doubled recovery rates of acute and subacute cases'' [17] , since vitamin B3 reduced the production of adrenochrome (an oxidized derivative of adrenaline that is neurotoxic) [18] . His contemporary, Thomas Ban, argued against vitamin treatment for schizophrenia, citing no replicable evidence from placebocontrolled trials to support vitamin supplementation [19] . Thus, the benefits of vitamin treatment in schizophrenia have long been debated, and, as discussed below, no clearcut answer has yet emerged, although there has been progress towards a more clear answer.
Vitamins

B Vitamins
B vitamins play an essential role in cellular metabolism, including transmethylation and oxidation/reduction reactions. Low blood levels of B vitamins are a relatively consistent finding in patients with schizophrenia. In a cross-sectional study, Kemperman and colleagues reported lower levels of serum vitamin B12 in 61 Dutch patients with schizophrenia when compared with healthy controls; no difference was found in folate and vitamin B6 levels between the groups [3] . In an earlier cross-sectional study, also in a Dutch population, Muntjewerff and colleagues demonstrated lower plasma folate levels in 35 schizophrenia patients compared with controls after adjusting for homocysteine levels, and an increased risk of schizophrenia with decreasing plasma folate levels; they found no difference in vitamin B6 and vitamin B12 levels [4] . In another cross-sectional study among Greek inpatients, there was no difference in plasma folate and B12 levels between patients and controls [20] . However, among medication-naïve first-episode outpatients with psychosis in India (with diagnosis of schizophrenia, schizoaffective disorder or schizophreniform after 6 months follow-up), Kale et al. showed lower plasma folate and B12 levels in patients versus controls [5] , suggesting an effect independent of antipsychotic medication treatment. Goff and associates [6] also reported low folate levels in a cohort of 91 schizophrenia outpatients, and found a significant inverse relationship between folate level and negative symptom severity among non-smoking patients; further work from this group has specifically related a common, low-functioning variant in methylenetetrahydrofolate reductase (MTHFR), a key enzyme in the folate metabolic pathway, to risk for negative symptoms [21] , related cognitive impairment [22] , and reduced prefrontal activation during executive function [23, 24] . The same variant in MTHFR, known as 667C [ T (rs1801133), has also been associated with increased schizophrenia risk in a large meta-analysis [25] , although at this time it has yet to emerge as a significant risk factor in genome-wide studies. Several recent B vitamin supplementation strategies show promise in schizophrenia. In a small, double-blind, placebo-controlled study, Godfrey et al. showed symptom and social recovery in 17 schizophrenia patients with baseline low folate levels who received daily methylfolate supplementation (15 mg/day) for 6 months [26] in addition to standard pharmacologic treatment. In a more recent crossover study, Levine and colleagues demonstrated symptom improvement in 42 schizophrenic patients with elevated homocysteine levels, supplemented with folic acid (2 mg/day), vitamin B6 (25 mg/day), and vitamin B12 (400 lg/day) [27] in addition to regular antipsychotic treatment. However, it is not evident from this study whether elevated homocysteine levels are required for the symptomatic benefits of treatment with folic acid, since all of the patients had hyperhomocysteinemia. In a small study of 28 patients on a stable dose of antipsychotic medication, Hill and colleagues found no difference in symptom response among patients who received folic acid (2 mg/day) versus placebo (both groups improved); however, among patients with at least one copy of the low functioning variant in the MTHFR gene (677T), negative symptoms improved more in the active treatment group than in the placebo group at trend level (p = .06) [28] . In one of the largest randomized, multicenter, controlled trials examining vitamin [29] . The folate ? B12 group showed significant improvement in negative symptom severity, but only when genotype was considered. Specifically, treatment response was strongly influenced by a genetic variant in FOLH1 (rs202676), which facilitates the translocation of dietary folates across the intestinal lumen. While transport of supplemental (synthetic) folic acid does not require FOLH1, patients with the low-functioning variant had lower levels of blood folate (i.e., reflecting pre-trial dietary folate intake) at baseline. This may account for the diminished response to supplementation in this subset of patients, as it may have taken longer to achieve a therapeutic CNS folate level, and sustained folate exposure was necessary to achieve negative symptom reduction. An important limitation of the cross-sectional studies described above is that nutrient deficiency may reflect a downstream consequence of symptoms (e.g., impaired motivation to eat a healthy diet), rather than a primary cause of pathophysiology. However, somewhat stronger evidence-albeit still correlational-comes from longitudinal studies of populations exposed to famine during neurodevelopment. Although its age of onset is not usually until the second or third decade of life, schizophrenia is widely posited to reflect a delayed consequence of altered neurodevelopment [30] . Local incidence of schizophrenia transiently doubled two decades after the Dutch Hunger Winter of 1944-1945 [31] and the Chinese famine in the late 1950s [32] . Among the birth cohort conceived while exposed to the peak of the Dutch famine, there was also an increase in neural tube defects [31] . Given that neural tube defects are strongly associated with prenatal folate deficiency [33] , a parsimonious explanation for both diagnoses would be a perturbation in the folate metabolic pathway.
While a more thorough discussion of the mechanisms by which prenatal folate deficiency contribute to the development of schizophrenia is outside of the scope of this article, we emphasize three ideas proposed by Brown and Susser [34] , who elaborate that folate deficiency (i) interferes with DNA synthesis and repair, leading to an increase in de novo mutations; (ii) interferes with DNA methylation and gene expression; and (iii) limits the conversion of homocysteine to methionine, resulting in a buildup of homocysteine in the developing brain. Further, investigators in the Prenatal Determinants of Schizophrenia (PDS) study analyzed banked sera from a US cohort of mothers during pregnancy, finding that elevated third trimester homocysteine (which is inversely related to folate) was associated with a 2-fold increase in schizophrenia risk in offspring [35] . However, Brown and Susser also point out that elevated homocysteine levels may contribute to the development of schizophrenia through other mechanisms (dysfunction of NMDA receptor, placental vasculopathy leading to fetal hypoxia) than by disruption in folate metabolism [34] .
Vitamin D
Vitamin D is a critical regulator of calcium metabolism, and also plays roles in gene expression and immune function. Vitamin D deficiency has been implicated by several schizophrenia investigators, although conclusions are limited by small sample size and the lack of comparison with healthy individuals. Within a cross-sectional study of 102 psychiatric inpatients in New Zealand, of 19 patients who had severe vitamin D deficiency, 13 had schizophrenia (34 vs 9.4 % other psychiatric diagnoses) [7] . Vitamin D deficiency and associated psychosis has been noted in darkskinned immigrant populations. In a retrospective chart review of 18 first-generation immigrants from Africa and Haiti with acute psychosis, all patients had vitamin D levels in the insufficient range [36] ; however, many of the clinical descriptions of the episodes were not consistent with a schizophrenia diagnosis, and only seven of these patients went on to be diagnosed with schizophrenia. Similarly, in a cross-sectional study of Norwegian patients, vitamin D deficiency was present in 80 % of the psychotic immigrant population with dark complexions. Among native-born Norwegians with psychosis, 43 % had vitamin D deficiency and had lower serum vitamin D levels compared with the reference sample [8] . In a cross-sectional study of 35 adolescent inpatients, 33.7 % of patients were vitamin D deficient; of those deficient, 40 % exhibited psychotic features compared with 16 % of patients who were not vitamin D deficient [9] . In a case-control study, Crews et al. found significantly lower levels of serum vitamin D among 69 first-episode psychosis inpatients compared with matched healthy controls [10] (OR of being vitamin D deficient was 2.99 in patients relative to controls). In another small study of first-episode patients, more severe negative symptoms and cognitive impairment were correlated with lower vitamin D levels. These patients had not received more than a total of 4 months of antipsychotic treatment [37] . Finally, in a recent meta-analysis, Belvederi Murri et al. found that patients with psychotic disorders (mainly schizophrenia) had consistently lower vitamin D levels compared with healthy controls [11] . The authors examined seven studies overall for a total of 523 patients and 7,545 controls. Of note, there was heterogeneity of effect size, and most studies were case-control or cross-sectional. As with all observational studies, we emphasize that the results have to be taken with caution, given there may be many potential confounding variables that are present in patients with schizophrenia and also affect vitamin D levels, such as insufficient nutrient intake or little sunlight exposure.
Vitamin D deficiency early in life may also contribute to schizophrenia risk. McGrath et al. examined a Danish cohort of over 400 patients with schizophrenia and carefully matched controls in which neonatal dried blood spots had been collected [38] . Among individuals in the lowest quintiles of neonatal vitamin D, there was a 2-fold elevated risk of schizophrenia compared with those in higher quintiles. Interestingly, those neonates with the highest vitamin D levels also had an increased risk of schizophrenia. In a birth cohort of over 2,000 people in the UK, Sullivan et al. did not find an association between maternal vitamin D levels and risk of psychotic illness at age 18 [39] . However, it is likely that some individuals at this age have not yet experienced onset of the illness; it will be important to follow the cohort over the subsequent years.
Intervention studies have had mixed results. In a Finnish birth cohort of over 9,000 people, vitamin D supplementation with at least 2,000 IU/day in males in the first year of life reduced the risk of schizophrenia by 77 % (RR .23) compared with those receiving less than 2,000 IU/day; these findings did not hold true in females [40] . The authors hypothesize that early vitamin D supplementation is crucial for pro-differentiating signals in the developing brain, and potentially also for normal brain recovery after insult. In the study of immigrant population discussed above [36] , Dealberto provided daily vitamin D supplementation of 1,000 IU/day in addition to ongoing antipsychotic treatment, and concluded there were no changes in psychiatric symptoms after vitamin supplementation.
Vitamins C and E
Vitamins C and E are antioxidants that protect against cellular damage due to inflammation or highly reactive oxygen-containing molecules. In a small cross-sectional study among 20 inpatients with schizophrenia and 15 controls, patients had lower fasting vitamin C levels and lower urinary vitamin C excretion after 1.0 g oral vitamin C load [12] . The investigators then examined plasma vitamin C levels in a separate group of schizophrenia patients (n = 15) versus controls after vitamin C supplementation (70 mg/day for 4 weeks in addition to antipsychotic treatment); the plasma vitamin C levels were similar in both groups, but urinary excretion was lower among the patient sample, suggesting an impairment in vitamin C metabolism. In another small study among 14 inpatients with schizophrenia in India, plasma vitamin E and C levels were significantly lower when compared with control subjects [13] .
One study reported a decrease in the Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Syndrome Scale (PANSS) scores among patients on antipsychotic treatment after supplementation with vitamin C (500 mg/day), vitamin E (400 IU/day), and omega-3 fatty acids [41] ; however, given the combination treatment it is difficult to conclude what effects are due to vitamin supplementation alone. A randomized, placebo-controlled study by Bentsen et al. [42] also supplemented vitamin C (364 mg/day) and vitamin E (1,000 mg/day) to patients with schizophrenia on antipsychotic medication; among those patients with low red blood cell polyunsaturated fatty acids (PUFAs), the vitamin supplementation actually impaired recovery from acute psychosis compared with placebo. The authors hypothesize that vitamin E at a high-enough dose can act as a pro-oxidant if there is inadequate antioxidant activity, thus increasing oxidative stress; it could also inhibit the beneficial c-and d-tocopherols. They posit that vitamin C may counteract some detrimental effects of vitamin E. Beauclair et al. performed an 8-week, open-label trial of progressively increasing doses of vitamin C (max dose 8 g/day) among 13 patients with residual symptoms of schizophrenia despite antipsychotic treatment [43] . Ten of the thirteen patients showed improvement on Clinical Global Impression (CGI) scores and plasma vitamin C levels increased over the 8 weeks of treatment. The authors report that most of the symptomatic improvement occurred in the positive symptom domain. Notably, there was no control group in this study, and the weekly study visits with medical staff may also have contributed to improvement in psychotic symptoms.
In a prospective, double-blind, placebo-controlled study of 40 outpatients in India, Dakhale et al. [44] examined vitamin C supplementation (500 mg/day) for 8 weeks in patients with schizophrenia taking second-generation antipsychotics. The authors found that in the vitamin C group, there was a reduction in serum malondiahldehyde (MDA) levels (a measure of antioxidants), an increase in plasma ascorbic acid levels, and a decrease in BPRS scores. Of note, similar trends were also present in the placebo group. When the two groups were compared, the vitamin C group had a significantly greater decrease in MDA and BPRS scores and a significant increase in ascorbic acid levels. It is a not clear whether there is some interaction between second-generation antipsychotic medications and vitamin C, or if vitamin C acts through another mechanism. The authors propose that vitamin C may inhibit peroxidation of phospholipids and act as a free radical scavenger. While the overall study is well designed, the results must be taken cautiously given the small number of patients.
Vitamin A
Vitamin A is converted to retinoic acid, which plays a critical role in neuronal differentiation and migration; a disruption in the process could contribute to the underlying pathophysiology of schizophrenia. In the PDS study (detailed above) [35] , investigators found that low maternal vitamin A levels during the second trimester of pregnancy are associated with a 3-fold increase in schizophrenia spectrum disorders; no association was found during the third trimester (analysis not done on first trimester samples) [45] . The study finding is consistent with the hypothesis that prenatal vitamin deficiency plays a role in the development of schizophrenia. Further, the finding of elevated homocysteine levels (associated with low folate levels) in this cohort was present only in the third trimester, suggesting specific vitamin levels are crucial at different stages of development for the prevention of schizophrenia.
Conclusions and Future Directions
Vitamin supplementation, particularly with folic acid, vitamin B12 and vitamin D, may play an important role in the treatment of schizophrenia within certain subgroups. In those patients who are vitamin D deficient (darker skin, living at latitude with less sunlight), supplementation with vitamin D may be protective among those vulnerable to psychosis. Among those patients with specific genetic variants in the folate metabolic pathway, supplementation with both folate and vitamin B12 can be beneficial, especially in improving negative symptoms. While there is less compelling evidence for treatment with other vitamins, and even some evidence to the contrary, further studies are necessary to make treatment decisions.
A number of questions remain. For example, should it be common practice to supplement patients' antipsychotic medications with a cocktail of vitamins? For how long should treatment be continued? There is a clear need for larger, randomized control trials examining vitamin treatment, in particular in relation to dosing, genotype, and specific types of symptoms (e.g., negative symptoms or cognitive symptoms), and in combination with specific antipsychotic medications. It would also be informative to examine the incidence of schizophrenia in underdeveloped countries with poor prenatal care and malnutrition; blood samples and prenatal serum could help determine levels of deficiency, and ideally response to supplementation. Further, it may be valuable to examine patterns of schizophrenia incidence and severity in countries that have recently adopted mandatory folic acid fortification of grain products. Finally, while vitamins are generally considered safe and well tolerated, several investigators have linked high doses of vitamin intake to cancer risk [46] , although this has been disputed in other meta-analyses [47] . Additionally, it must be noted that there is always the possibility of a publication bias given the lack of negative studies published. Although recent studies demonstrate promise for vitamin supplementation in schizophrenia, as with all interventions, patients and their providers will ultimately need to consider both the risk and benefit sides of the equation prior to initiating treatment.
